priors.science/reviews/alzheimers-disease-treatment

Alzheimers Disease Treatment

The current evidence on 12 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

12claims tracked
202primary papers reviewed
4 Jun 2026latest evidence review
Weeklyre-scored against new papers
2 Established · 6 Likely · 4 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableCholinesterase inhibitors give symptomatic benefitSymptomaticEstablished85%20
StablePlasma phosphorylated tau 217 detects Alzheimer's pathologyBiomarkersLikely78%20
StableLecanemab slows decline in early Alzheimer's diseaseAmyloid ImmunotherapyLikely75%20
StableMemantine helps moderate-to-severe Alzheimer's diseaseSymptomaticLikely75%20
StableDonanemab slows decline in early Alzheimer's diseaseAmyloid ImmunotherapyLikely73%20
StableMidlife cardiovascular risk control cuts dementiaPreventionLikely72%20
StableMultidomain lifestyle slows declinePreventionLikely68%20
StableExercise reduces cognitive declinePreventionUncertain57%20
StableAmyloid positron emission tomography reduction predicts benefitBiomarkersUncertain55%20
StableMemantine plus cholinesterase inhibitor beats monotherapySymptomaticUncertain55%20
StableAducanumab clinically beneficialAmyloid ImmunotherapyUncertain43%20
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic